Dendritic cells expressing soluble CTLA4Ig prolong antigen-specific skin graft survival

Immunology and Cell Biology

Volumn 88, Issue 8, 2010, Pages 846-850

  Ierino, Francesco L ^a,b   Mulley, William ^b   Dodge, Natalie ^b   Li, Yu Qin ^b   Mouhtouris, Effie ^b   Christiansen, Dale ^b   Sandrin, Mauro S ^b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CTLA 4Ig; DCs; skin graft

Indexed keywords

ABATACEPT; GREEN FLUORESCENT PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; C57BL 6 MOUSE; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO CULTURE; LENTIVIRINAE; LYMPHOCYTE; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SKIN GRAFT; SKIN TRANSPLANTATION; SPLEEN CELL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE; DENDRITIC CELLS; GRAFT SURVIVAL; IMMUNOCONJUGATES; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSGENES;

MURINAE; MUS;

EID: 78649331681     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2010.58     Document Type: Article

References (34)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
2. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
3. Rogers NJ, Lechler RI. Allorecognition. Am J Transplant 2001; 1: 97-102.
4. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 2004; 15: 61-76.
5. Morel PA, Feili-Hariri M, Coates PT, Thomson AW. Dendritic cells, T cell tolerance and therapy of adverse immune reactions. Clin Exp Immunol 2003; 133: 1-10.
6. Morelli AE, Hackstein H, Thomson AW. Potential of tolerogenic dendritic cells for transplantation. Semin Immunol 2001; 13: 323-335.
7. O'Rourke RW, Kang SM, Lower JA, Feng S, Ascher NL, Baekkeskov S et al. A dendritic cell line genetically modified to express CTLA4-IG as a means to prolong islet allograft survival. Transplantation 2000; 69: 1440-1446.
8. Zhang M, Wang Q, Liu Y, Sun Y, Ding G, Fu Z et al. Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival. J Mol Med 2004; 82: 240-249.
9. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-569.
10. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-252.
11. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-1101.
12. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-774.
13. Brady JL, Lew AM. Additive efficacy of CTLA4Ig and OX40Ig secreted by genetically modified grafts. Transplantation 2000; 69: 724-730.
14. Feng S, Quickel RR, Hollister-Lock J, McLeod M, Bonner-Weir S, Mulligan RC et al. Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4Ig. Transplantation 1999; 67: 1607-1613.
15. Fernandes JR, Duvivier-Kali VF, Keegan M, Hollister-Lock J, Omer A, Su S et al. Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectors. Transpl Immunol 2004; 13: 191-200.
16. Gainer AL, Korbutt GS, Rajotte RV, Warnock GL, Elliott JF. Expression of CTLA4-Ig by biolistically transfected mouse islets promotes islet allograft survival. Transplantation 1997; 63: 1017-1021.
17. Kimura F, Gotoh M, Tanaka T, Luo Z, Miyazaki J, Uede T et al. Locally expressed CTLA4-Ig in a pancreatic beta-cell line suppresses accelerated graft rejection response induced by donor-specific transfusion. Diabetologia 2002; 45: 831-840.
18. Lew AM, Brady JL, Silva A, Coligan JE, Georgiou HM. Secretion of CTLA4Ig by an SV40T antigen-transformed islet cell line inhibits graft rejection against the neoanti-gen. Transplantation 1996; 62: 83-89.
19. Sutherland RM, Brady JL, Georgiou HM, Thomas HE, Lew AM. Protective effect of CTLA4Ig secreted by transgenic fetal pancreas allografts. Transplantation 2000; 69: 1806-1812.
20. Lu L, Lee WC, Takayama T, Qian S, Gambotto A, Robbins PD et al. Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig). J Leukoc Biol 1999; 66: 293-296.
21. Sun W, Wang Q, Zhang L, Liu Y, Zhang M, Wang C et al. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin. Transplantation 2003; 76: 1351-1359.
22. Takayama T, Morelli AE, Robbins PD, Tahara H, Thomson AW. Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro. Gene Ther 2000; 7: 1265-1273.
23. Jorgensen TN, Haase C, Michelsen BK. Treatment of an immortalized APC cell line with both cytokines and LPS ensures effective T-cell activation in vitro. Scand J Immunol 2002; 56: 492-503.
24. Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, Okumura K et al. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 1981; 127: 34-38.
25. Mellor A. Indoleamine 2,3 dioxygenase and regulation of T cell immunity. Biochem Biophys Res Commun 2005; 338: 20-24.
26. Beutelspacher SC, Pillai R, Watson MP, Tan PH, Tsang J, McClure MO et al. Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 2006; 36: 690-700.
27. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196: 459-468.
28. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164: 3596-3599.
29. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 2002; 168: 3771-3776.
30. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-1372.
31. Barratt-Boyes SM, Thomson AW. Dendritic cells: tools and targets for transplant tolerance. Am J Transplant 2005; 5: 2807-2813.
32. Mulley WR, Wee JL, Christiansen D, Milland J, Ierino FL, Sandrin MS. Lentiviral expression of CTLA4Ig inhibits primed xenogeneic lymphocyte proliferation and cytokine responses. Xenotransplantation 2006; 13: 248-252.
33. Layton DS, Bean AG, Dodge NM, Strom AD, Sandrin MS, Ierino FL. Differential cytokine expression and regulation of human anti-pig xenogeneic responses by modified porcine dendritic cells. Xenotransplantation 2008; 15: 257-267.
34. McKenzie IFC, Morgan GM, Melvold RW, Kohn HI. A new H-2 mutant in BALB/c that identifies a locus associated with the D region. Immunogenetics 1977; 3: 333.